Improving urine tests to better assess bladder cancer treatment outcomes
Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients
['FUNDING_U01'] · RESEARCH INST OF FOX CHASE CAN CTR · NIH-10898906
This study is testing a new urine test that looks for DNA changes linked to bladder cancer, helping patients who have had chemotherapy find out if they really need surgery, so they can avoid unnecessary procedures and complications.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH INST OF FOX CHASE CAN CTR (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10898906 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing a urine test called UTeRD, which analyzes DNA from urine samples to detect mutations associated with bladder cancer. By using next-generation sequencing, the study aims to accurately identify patients who have achieved a complete response to neoadjuvant chemotherapy, potentially allowing them to avoid radical cystectomy. The goal is to improve the accuracy of clinical assessments of bladder cancer status, thereby reducing unnecessary surgeries and associated complications. Patients who have undergone chemotherapy for muscle-invasive bladder cancer may benefit from this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates are patients with muscle-invasive bladder cancer who have received neoadjuvant chemotherapy.
Not a fit: Patients who have not undergone chemotherapy or those with non-muscle invasive bladder cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate assessments of bladder cancer treatment responses, reducing the need for invasive surgeries.
How similar studies have performed: Previous research has shown promise in using urine-based tests for cancer detection, indicating potential success for this novel approach.
Where this research is happening
PHILADELPHIA, UNITED STATES
- RESEARCH INST OF FOX CHASE CAN CTR — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ABBOSH, PHILIP — RESEARCH INST OF FOX CHASE CAN CTR
- Study coordinator: ABBOSH, PHILIP
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bladder Cancer